Trial Profile
Evaluation of the efficacy and safety of intravitreal bimonthly injection of aflibercept for age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jan 2018
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 27 Dec 2017 Status changed from active, no longer recruiting to completed.
- 12 Dec 2015 New trial record